ActX, a biotech company based in Seattle, has raised $6M in equity funding and is seeking an additional $107,000 to further its work in genetic profile testing.
The company, founded in 2013, uses genetic testing to aid medical professionals in screening patients for conditions based on hereditary risks. The technology empowers physicians to make decisions based on a patient’s genetic profile and helps patients understand how genetic conditions affect their children.
ActX is the latest Seattle biotech to raise funding in 2022. Other Seattle-based companies, such as Bonum Therapeutics, raised $93M in a Series A, along with Cajal Neuroscience raising $96M in a Series A round in November 2022.